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Abstract
A graft copolymer with pendant drug segment can fold into nanostructures in a protein folding-
like manner. The graft copolymer is constructed by directly polymerizing γ-camptothecin-
glutamate N-carboxyanhydride (Glu(CPT)-NCA) on multiple sites of poly(ethylene glycol)
(PEG)-based main chain via the ring open polymerization (ROP). The “purely” conjugated
anticancer agent camptothecin (CPT) is hydrophobic and serves as the principal driving force
during the folding process. When exposed to water, the obtained copolymer, together with
doxorubicin (Dox), another anticancer agent, can fold into monodispersed nanocarriers (with a
diameter of around 50 nm) for dual-drug delivery. Equipped with a PEG shell, the nanocarriers
displayed good stability and can be internalized by a variety of cancer cell lines via the lipid raft
and clathrin-mediated endocytotic pathway without premature leakage, which showed a high
synergetic activity of CPT and Dox toward various cancer cells. In vivo study validated that the
nanocarriers exhibited strong accumulation in tumor sites and showed a prominent anticancer
activity against the lung cancer xenograft mice model compared with free drugs.
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1. Introduction
Evolution of drug resistance in cancer cells has been attributed as a major factor in the
failure of many forms of monotherapy [1–2]. To prevent evolutionary development, it often
requires a high drug dose to kill the whole cancer cell population; whereas it always induces
severe side effects [3–4]. The limitations of monotherapy can be circumvented by
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synergistic combination of multiple anticancer agents which allows for reduction of the drug
dose and offers a potential benefit to simultaneously act on several cancer targets, therefore
preventing or delaying the emergence of drug resistance [5]. However, the traditional
combination strategy, namely the drug cocktail, shows limited success in clinics due to the
non-coordinated distributions of drugs after administration [6]. Pharmacokinetic interactions
are also observed in these combination therapies, raising concern about the synergistic
toxicity of these cocktails [7–8]. For example, a combination of rapamycin (RAPA) and
cyclosporine (CsA) produces renal dysfunction, since the pharmacokinetic interaction
between RAPA and CsA highly increases the concentration of CsA in kidney [7]. In
addition, the difference in solubility, potency, pharmacokinetics and bioavailability between
drugs makes the dose schedule extremely challenging in the cocktail therapy [9–11].
Nanocarriers have been developed as an important strategy for drug delivery due to their
capabilities of enhancing drug solubility, improving pharmacokinetics and preferentially
accumulating in tumor by the enhanced permeability and retention (EPR) effect [12–17].
Therefore, the nanocarrier-based combination therapy not only has the loading potency of
the multiple agents, but also accommodates their biodistribution and plasma elimination,
realizing an extremely simple dose optimization [18–19]. Polymeric micelles are one of the
most common nanoparticle systems for co-delivery of multiple drugs due to their
physicochemical stability and low toxicity [12, 20–21].
Topoisomerase (Top) represents one of the most popular targets in cancer chemotherapy. Its
inhibitors can block the DNA ligation step during cell cycling, and induce irreversible single
and double stranded DNA breaks during transcription and replication, thereby leading to
apoptosis and cell death [22]. Both camptothecin (CPT) and doxorubicin (Dox) are potent
Top inhibitors, but they interfere with the action of Top I and II, respectively. CPT as the
Top I inhibitor has shown potent anti-tumor efficacy in a broad spectrum of cancers in clinic
[23–24]. However, certain clinical limitations such as resistance of cancer cells impair its
clinical application [25–26]. It has been postulated that the reduced Top I activity following
the CPT treatment could be compensated by the Top of the other class (Top II), because the
actions of both enzymes are partially overlapping [27]. It has been proven that the increase
of Top II activity occurred in cancer cells resistant to CPT [28], and Top II inhibitor Dox
showed a collateral cytotoxicity on the CPT adapted cancer cells [29]. Therefore, the
concomitant use of both Top I and Top II inhibitors might elicit synergistic effects and
prevent the emergence of drug resistance [30]. Polymeric nanocarriers have provided a
novel combination strategy for simultaneously delivering multiple agents to tumor sites via a
single vehicle. Coordination of the solubility, pharmacokinetics and biodistribution of
multiple drugs by nanocarriers allows this strategy to overcome the problems commonly
associated with traditional drug cocktail methodology.
We designed a new graft copolymer, which can fold into a polymeric nanomicelle for co-
delivery of two small-molecule anticancer drugs: CPT and Dox. Unlike the traditional
micelle assembled from AB type of amphiphilic diblock copolymer, the current nanocarrier
was folded by a structurally well-defined graft copolymer in which the side chain associated
together as the hydrophobic micelle core and poly(ethylene glycol) (PEG) main chain
entangled around it. As depicted in Figure 1A, the graft copolymer was constructed from
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three monomers by a two-step polymerization. The “tee joint”-like monomer I and monomer
II were first condensed into a linear multiblock copolymer, to which a CPT-linked monomer
III γ-camptothecin-glutamate N-carboxyanhydride (Glu(CPT)-NCA) was subsequently
grafted by an amine-initiated ring open polymerization (ROP) [31–32]. The resulting graft
copolymer displayed a well-defined structure where the main chain was composed of the
hydrophilic PEG and the side chains were polypeptide chains “purely” conjugated with
hydrophobic drugs (Figure 1B). Once reconstituted with water, this graft copolymer
(“denatured” state in organic solvents, designated “Sd”) folded into a uniform nanocarrier
(“native” state, designated “Sn”), in which the side chains were assembled into a
hydrophobic core wrapped around by the main PEG chain as a shell. Unlike the traditional
micelles assembled by a linear unit, this nanocarrier was folded from a grafted unit, making
the final structure more compact and stable [33]. In addition, the hydrophobic core also
provided accommodation for co-encapsulating other hydrophobic anticancer drugs through
physical interactions such as π-π stacking [9, 34–35]. In our co-delivery system, Dox was
physically encapsulated in the hydrophobic core, while the CPT was covalently linked on
side chains which can be released via the degradation of ester linkage by the intracellular
esterase [36–37].
2. Materials and methods
2.1. Material
All chemicals were obtained from commercial sources and used without further purification.
Tris(2-aminoethyl)amine, di-t-butyl dicarbonate (Boc2O), trifluoroacetic acid (TFA), N,O-
bis(trimethylsilyl) acetamide (BSA) and triphosgene were purchased from Sigma Aldrich.
N,N′-diisopropylcarbodiimide (DIPC), triethylamine (Et3N) and 4-dimethylaminopyridine
(DMAP) were obtained from Acros Organics. N-hydroxylsuccinimide (NHS)
bifunctionalized PEG5000 (NHS-PEG5000-NHS) was purchased from Nanocs Inc. CPT and
Dox were purchased from Alfa Aesar. Boc-L-glutamic acid 5-tert-butyl ester (Boc-Glu-
OtBu) was ordered from Chem-Impex International Inc. All the organic solvents for
synthesis and analysis were ordered from Fisher Scientific Inc. and used as received.
2.2. Synthesis of graft copolymer 5
2.2.1. Synthesis of monomer I (2)—The monomer I, N,N-bis(2-aminoethyl)-N-[2-(tert-
butylcarbamoyl)ethyl-amine (2), was synthesized as reported [38–39]. Briefly, a chloroform
solution of Boc2O (1 g, 4.6 mmol, 0.1 equiv) was added dropwise into a stirred solution of
tris(2-aminoethyl)amine (1) (6.7 g, 46 mmol) in 300 mL of chloroform at 0 °C. The reaction
was allowed to warm to room temperature and stirred overnight. The reaction was stopped
by 15 mL of distilled deionized (DD) water. After stirred for 5 min, the organic phase was
separated. The aqueous phase was re-extracted with 30 mL of chloroform. The combined
organic phase was dried with Na2SO4, then concentrated under vacuum to give crude
compound 2 which was purified by silica gel chromatography using CHCl3/MeOH/
concentrated aqueous NH4OH (v/v/v, 10/5/1) as eluent. The purified monomer I was given
as viscous oil (1.05 g, 92%). 1H NMR (300 MHz, DMSO-d6): δ 6.81 (t, 1H), 2.95 (q, 2H),
2.81 (brs, 4H), 2.52 (t, 4H), 2.38 (q, 6H), 1.39 (s, 9H). ESI-MS calcd for C11H26N4O2
246.21, found 247.21 [M + H]+.
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2.2.2. Synthesis of multiblock copolymer 3 by condensation polymerization—
Multiblock copolymer 3 was synthesized as the method we reported before [40]. Briefly,
Monomer I (2) and NHS-PEG5000-NHS (monomer II) was dried in CaCl2 desiccator for two
days before synthesis. One gram of NHS-PEG5000-NHS (0.2 mmol, 1 equiv) was dissolved
in 4 mL of dry dimethyl formamide (DMF), followed by adding 0.5 mL of monomer I (52.1
mg, 0.2 mmol, 1 equiv) solution in DMF at N2 atmosphere. The reaction was initiated by
adding 140 μL of dry Et3N. Two days later, the reaction mixture was poured into 50 mL of
diethyl ether. The precipitate was washed twice with diethyl ether, dried in vacuum and
yield as white powder (860 mg, 81%). 1H NMR (300 MHz, CDCl3): δ 4.21 (t, 2H), 3.63 (s,
448H), 3.17 (m, 4H), 2.55 (t, 6H), 2.37 (brs, 4H), 1.43 (s, 9H).
2.2.3. TMS activated polymer 4—To remove the protecting group Boc, polymer 3 was
dissolved in 10 mL of dichloromethane (DCM) and TFA mixture (v/v, 1/1). The scavenger,
phenol (140 mg), was also added into the mixture to minimize the side reaction. The
reaction mixture was stirred at room temperature for 1 h. The organic solvent was
evaporated in vacuum and the residue was washed with diethyl ether. After removing the
remaining organic solvent in vacuum, the residue was dissolved in water and dialyzed
against DD water with cellulose tubing (molecular weight cut-off (MWCO): 12 kDa). The
resulting solution was lyophilized and dried in CaCl2 desiccator.
The amine groups on the multiblock copolymer were activated with N-trimethylsilyl (TMS)
as initiator for graft polymerization. The dry polymer (200 mg) was mixed with 5 mL of
anhydrous benzene. After polymer was completely dissolved, 2 mL of N,O-
bis(trimethylsilyl) acetamide (BSA) was added. The reaction was stirred at room
temperature for 24 h. Anhydrous hexane (20 mL) was added into the reaction mixture to
precipitate the product. The white precipitate was washed three times with anhydrous
hexane and dried under vacuum to give polymer 4 in quantitative yield. 1H NMR (300 MHz,
CDCl3): δ 4.21 (t, 2H), 3.64 (s, 448H), 3.20 (m, 4H), 2.60 (m, 6H), 2.12 (m, 4H), 0.01 (s,
9H).
2.2.4. Graft copolymer 5—The ROP of the side chain was initiated by TMS activated
amines [31]. Briefly, monomer III (121.1 mg) and polymer 4 (62.1 mg) was suspended in 5
mL of dry chloroform. The yellow suspension gradually turned clear after adding 75 μL of
dry Et3N. The reaction gradually became turbid over time, indicating the successful
polymerization. After 48 h, the reaction mixture was poured into 30 mL of diethyl ether to
precipitate the product. After washing three times with diethyl ether, the precipitate was
dried under vacuum to give graft copolymer 5. Note: extensively washing of polymer 4 is
essential for the graft polymerization. The trace amount of BSA in polymer 4 can induce
considerable side reaction, resulting in failure of graft polymerization and large aggregation
during folding. Directly initiating graft polymerization with amine (the intermediate of
polymer 4) is also applicable, but with less ROP efficiency [31]. 1H NMR (300 MHz,
DMSO-d6): δ 8.68 (s, 10H), 8.14 (m, 20H), 7.82 (m, 10H), 7.69 (m, 10H), 7.05 (s, 10H),
5.47 (m, 20H), 5.25 (br, 20H), 4.01 (s, 10H), 3.51 (s, 448H), 2.12 (br, 50H), 0.86 (br, 30H).
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2.3. Synthesis of monomer III
2.3.1. Synthesis of Boc-Glu(CPT)-OtBu—To the suspension of CPT (0.8 g) in
chloroform (50 mL), Boc-Glu-OtBu (2.4 g), DIPC (2.4 mL) and DMAP (0.154 g) were
separately added. The suspension was stirred at room temperature and the reaction gradually
turned clear in around 1 h. The reaction was stopped by adding 30 mL of saturated aqueous
NH4Cl solution. The organic phase was separated, washed with brine and dried by Na2SO4.
The organic solvent was removed by evaporation under vacuum and the crude product was
purified by silica gel chromatography eluted with hexane/EtOAc (v/v = 2/1, then 1/1 and
then EtOAc only). The pure product was given as white powder with yield of 80%. 1H NMR
(300 MHz, DMSO-d6): δ 8.68 (s, 1H), 8.14 (t, 2H), 7.86 (t, 1H), 7.71 (t, 1H), 7.22 (d, 1H),
7.07 (s, 1H), 5.50 (s, 1H), 5.28 (s, 1H), 3.88 (m, 1H), 2.62 (m, 2H), 2.17 (t, 2H), 1.89 (q,
2H), 1.37 (s, 18H), 0.92 (t, 3H). ESI-MS calcd for C34H39N3O9 633.28, found 634.27 [M +
H]+.
2.3.2. Glu(CPT)-OH—The compound Boc-Glu(CPT)-OtBu was dissolved in 10 mL of
DCM at 0 °C. TFA (10 mL) was then added into the reaction. The mixture was allowed to
warm to room temperature and stirred for 1.5 h. The solvent was removed under vacuum
and the product was then precipitated with diethyl ether. After washing three times with
ether, the precipitate was dried under vacuum for next step reaction (yield, 90%). 1H NMR
(300 MHz, DMSO-d6): δ 8.68 (s, 1H), 8.15 (t, 2H), 7.86 (t, 1H), 7.71 (t, 1H), 7.09 (s, 1H),
5.51 (s, 2H), 5.28 (s, 2H), 3.96 (t, 1H), 3.46 (brs, 2H), 2.76 (m, 2H), 2.16 (m, 2H), 2.05 (m,
2H), 0.93 (t, 3H). ESI-MS calcd for C25H23N3O7 477.16, found 478.16 [M + H]+.
2.3.3. Glu(CPT)-NCA (monomer III)—Glu(CPT)-OH (280 mg) was added into 300 mL
of anhydrous tetrahydrofuran (THF). The mixture was sonicated in ultrasonic water tank for
couple minutes to disperse Glu(CPT)-OH in THF. After adding triphosgene (170 mg), the
suspension was stirred at 48 °C for 2 h. The suspensions gradually become clear, indicating
the completion of the reaction. Note: sufficient solvent THF in reaction is important;
otherwise it will not turn clear in 2 h. The reaction was concentrated under vacuum and the
yellow residue was re-dissolved in 15 mL of anhydrous THF. The crude product was
precipitated with 30 mL of anhydrous hexane. The precipitate was collected by centrifuge,
washed twice with anhydrous THF/hexane mixture (v/v, 1/2), dried in the vacuum
desiccators (yield, 70%). 1H NMR (300 MHz, DMSO-d6) δ 9.19 (s, 1H), 8.69 (s, 1H), 8.15
(t, 2H), 7.87 (t, 1H), 7.71 (t, 1H), 7.13 (s, 1H), 5.51 (s, 2H), 5.27 (s, 2H), 4.46 (m, 0.5H),
3.59 (m, 0.5H), 2.74 (t, 2H), 2.15 (q, 2H), 1.98 (m, 2H), 0.93 (t, 3H).
2.4. Folding graft copolymer into nanocarriers
Graft copolymer 5 was first dissolved in N-methylpyrrolidone (NMP) to obtain a clear
solution with concentration of 10 mg/mL. To obtain the MB-20 nanocarriers, 1 mL of the
graft copolymer solution was quickly added into 6 mL of DD water with vigorous shaking.
The micelle solution was then sonicated for 20 cycles (1 s each with a duty cycle of 20%).
The homogenous micelle solution was dialyzed against DD water for 24 h at room
temperature to completely remove the organic solvent NMP. The DD water was frequently
changed during the dialysis process. The nanocarrier solution was passed through 0.45 μm
SFCA syringe filter (Corning Inc, Corning, NY). The folded micelle was stored at 4 °C for
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further characterization. For long-term storage, 10 mL of micelle solution was mixed with
100 mg of cryoprotectant hydroxypropyl-β-cyclodextrin (HPβCD), frozen in liquid nitrogen
and lyophilized [41]. The lyophilization cake was stored at 4 °C for reconstitution with DD
water. To encapsulate Dox, Et3N-treated Dox (1 mg) was added into 1 mL of graft
copolymer solution in NMP and added slowly into DD water as described above. The
loading efficiency of Dox under this condition was 10 wt% of the total polymer weight.
Higher loading can be obtained by increasing the Dox amount during nanocarrier folding.
2.5. Characterization of graft copolymer and nanocarrier
Gel permeation chromatography (GPC) was performed on Waters 2695 Alliance®
separation model equipped with RI 2414 (410) detector. The separation of polymer was
achieved on Styrogel® HR4E column (Waters, 5 μm, 7.8 mm × 300 mm) at 50°C using
DMF containing 0.1 M LiBr as mobile phase. The molecular weight of polymer was
calibrated against standard PEG ranging from 112k–0.4k Dalton. For transmission electron
microscope (TEM) characterization, the copper TEM grid (Ted Pella Inc.) was plasma glow-
discharged for 20 s to create a hydrophilic surface on the carbon surface. Nanocarrier
solution (20 μL) was absorbed onto the freshly plasma-discharged carbon membrane for 30 s
and then blotted with a filter paper to remove excess solution. The grid was examined with
JEOL 2000FX at 100 kV. The particle size of nanocarrier was measured on the Malvern
Zetasizer NanoZS by dynamic light scattering (DLS).
2.6. In vitro drug release
The release of CPT from nanocarriers was monitored in 100% mouse serum by high
performance liquid chromatography (HPLC). Briefly, MB-20 solution (or Glu(CPT)-OH
solution) was mixed with 200% mouse serum to achieve a final concentration of 40 μM
(CPT equivalent). The mixtures were incubated at 37 °C. At indicated time points, 20 μL of
aliquot was sampled and precipitated with 80 μL of acetonitrile containing 0.5% TFA. After
10 min of incubation, the precipitate was spin down at 20,000g for 10 min and the
supernatant was analyzed by HPLC for quantification of the released CPT. The HPLC
system was equipped with Agilent pump, controller, autosampler and detector. The sample
was analyzed on Waters C-18 reverse phase column (4.6 × 250 mm, 5 μm) with a mobile
phase of acetonitrile/water (v/v, 35/65) plus 0.1% formic acid. The flow rate was set at 1
mL/min and absorbance of CPT was monitored at 370 nm.
The release of Dox was conducted using the dialysis method in the phosphate buffer (50
mM, pH 5.0 and 7.4) as reported [42]. MB-20/Dox in different pH phosphate buffers (400
μL, final concentration: 5 μM) was sealed in the dialysis tubing with MWCO 12 kDa and
was dialyzed against 25 mL of the corresponding pH phosphate buffer with stirring at 37 °C.
At indicated time points, 100 μL of release media was sampled for fluorescence
quantification of Dox (Ex/Em = 480/596 nm), and then returned to the release media to
maintain a constant volume. The release experiments were conducted in triplicate.
2.7. Dye micellization and fluorescence dequenching assay
To monitor the nanocarrier formation, dye merocyanine 540 was added into a serial
concentration of micelle solutions (from 0 to 1 mg/mL) to reach a final dye concentration of
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40 μM [43]. After equilibrating at room temperature overnight, the absorbance spectra of
dye/micelle mixtures were scanned by the microplate reader (Infinite M200 PRO, Tecan).
The fluorescence dequenching assay was determined by monitoring the fluorescence spectra
of CPT and Dox after disrupting the nanocarrier with surfactant sodium dodecyl sulfate
(SDS). Briefly, MB-20/Dox nanocarrier was incubated with 1% SDS solution at room
temperature. At the indicated time points, the fluorescence spectra of CPT and Dox were
scanned, respectively. Note: Dox fluorescence was scanned from the top of well, while CPT
signal was detected from the bottom. The spectra were merged by the Graphpad Prism 5
software (Graphpad software Inc).
2.8. In vitro cytotoxicity assay
In vitro cytotoxicity of CPT, Dox, MB-20 and MB-20/Dox was measured using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, the cancer
cells was seeded in 96-well plate at a density of 5,000 cells per well. After 12 h incubation, a
series of drug dilution (1 nM to 300 μM) were added into wells. After 48 h of drug
treatment, the cytotoxicity was measured using the MTT assay. To enhance the assay
sensitivity, Sorensen’s glycine buffer (0.1 M glycine, 0.1 M NaCl adjust pH to 10.5 with 0.1
N NaOH) was added into wells before absorbance assay [44–46]. The absorbance at
wavelength of 570 nm was measured using a microplate reader (Infinite M200 PRO, Tecan).
The half-maximal inhibitory concentration (IC50) was calculated by fitting a concentration –
absorbance curve using the Graphpad Prism 5 software (Graphpad software Inc.).
2.9. Cellular uptake study
For in vitro cellular uptake study, A549 cells were seeded into 6-well plate one day before
uptake study. When it was confluent, the monolayer was washed twice with FBS-free
DMEM medium and subsequently incubated with MB-20/Dox solution in DMEM (100 μM,
CPT equivalent) at 37°C. At the indicated time points, the drug was removed and the
monolayer was washed four times with Dulbecco’s phosphate-buffered saline (PBS). The
cells were lysed with 0.5 mL of 1% SDS solution for 10 min at room temperature. The
viscous solution was transferred into 1.5 mL centrifuge tube and sonicated for 2 cycles (1 s
each with a duty cycle of 20%). The drug concentration in the cell lysate was quantified by
fluorescence plate reader (CPT: Ex/Em = 370/450 nm; Dox: Ex/Em = 480/596 nm). The
total protein concentration of cell lysate was measured by the bicinchoninic acid assay (BCA
assay) kit (Sigma), and the cellular uptake was normalized to the total amount of cell protein
for each sample.
To study the endocytotic pathway, the cells were pretreated with sucrose (450 mM),
chlorpromazine (30 μM), nystatin (25 μg/mL), methyl-β-cyclodextrin (3 mM), sodium
azide/2-deoxyglucose (0.1%/50 mM) and wortmannin (0.8 mM) in serum-free DMEM
media for 1 h at 37 °C, respectively [47]. Nanocarriers were then added into each well at
CPT equivalent concentration of 6 μM and incubated with cells for another 2 h in the
presence of inhibitors. The cell monolayer was then washed and lysed. The drug
concentrations in the lysate were quantified as described above.
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To track the intracellular location of nanocarrier, the fluorescence of CPT and Dox in cancer
cells was monitored by the confocal laser scanning microscope (CLSM). Briefly, A549 cells
(40,000 cells) were seeded in a confocal microscope dish (MatTek) one day before
experiments. Cell monolayer was then washed with serum-free DMEM and incubated with
MB-20/Dox in DMEM (4 μM CPT equivalent) at 37 °C. At the indicated time points, drugs
were removed and the late endosomes and lysosomes were stained with LysoTracker®
Green DND-26 (50 nM) for 30 min (Life Tech, Grand Island, NY). The intracellular
distribution of nanocarrier was observed by CLSM (LSM 710, Zeiss).
2.10. Near-Infrared optical imaging of tumor-bearing mouse
The graft copolymer was labeled with Cy5.5-NHS ester as reported [48–49]. Briefly, 20 μL
of Cy5.5-NHS solution in chloroform (2.5 mg/mL) was added into 1 mL of graft copolymer
solution in NMP (10 mg/mL). The reaction was stirred in dark at room temperature
overnight, and then 500 μL of PBS was added. The reaction continued to stir for another 5 h
and then the Cy5.5 labeled graft copolymer was folded into nanocarrier as described above.
The nanocarrier solution was dialyzed against DD water for 48 h to remove the organic
solvent and free Cy5.5. After passing through 0.45 μm syringe filter, the micelle solution
was lyophilized with cryoprotectant HPβCD (1%).
Female naive athymic nude mouse (Strain name, J:NU) was purchased from Jackson Lab,
USA. The animal study protocol was approved by the Institutional Animal Care and Use
Committee of North Carolina State University. Tumor xenograft model was established in
the right dorsum of the nude mice by injecting 200 μL of A549 cells/Matrigel mixture (5 ×
106 cells per mouse; v/v = 1/1) (BD Biosciences). When tumors reached 300–400 mm3,
mice were intravenously injected by the MB-20/Cy5.5 nanocarrier at the Cy5.5 dose of 26
nmol/kg. The near-infrared (near-IR) optical images were taken on IVIS Lumina imaging
system (Caliper, USA) at 4, 24, 48 hand 72 h post injection. At 72 h post injection, the mice
were euthanized, and tumors as well as other tissues were harvested for ex vivo imaging.
Region-of-interest (ROI) was circled around the organs, and the fluorescence intensities
were analyzed by Living Image Software.
2.11. In vivo tumor ablation study
Tumor xenograft model was established in the right dorsum of the nude mice as described
above. Seventeen days after implantation when tumors reached an average volume of 80–
100 mm3, treatment was initiated by giving multiple doses (once every four days for a total
of six injections, q4d × 6) of PBS, free CPT (5 mg/kg), free Dox (5 mg/kg), MB-20 (10
mg/kg, CPT equivalent) and MB-20/Dox (10 mg/kg, CPT equivalent). All the groups were
intravenously injected via the tail vein with an exception of CPT (intraperitoneal injection)
due to its low solubility. The tumor sizes and body weights were closely monitored every
other day since the ninth day after implantation. The tumor volume for each time point was
calculated using the following formulation: length× width2/2.
2.12. Statistical analysis
Student’s t-test or ANOVA were utilized to determine statistical significance between
different groups. A p value < 0.05 was considered to be statistically significant.
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3. Results and discussion
3.1. Synthesis of graft copolymer
The graft copolymer was prepared via a facile two-step polymerization as illustrated in
Figure 2A and 2B. As a “tee joint”, partially protected tris(2-aminoethyl)amine 2 (monomer
I) condensed with bifunctional NHS-PEG5000-NHS (monomer II) to form an alternating
multiblock copolymer. After removing the Boc group, the third amino group on the “tee
joint” was liberated and then served as the initiator for side-chain polymerization. The ROP
of amino acid N-carboxyanhydrides, facilitated by TMS, gradually proceeded on the main
chain, leading to the chemically well-defined graft copolymer. It is notable that, for the first
time, CPT was directly polymerized into the side chains through ROP of Glu(CPT)-NCA,
different from the traditional polyglutamic acid CPT conjugation method [50–51]. Direct
polymerization of Glu(CPT)-NCA can guarantee 100% CPT conjugation to the residues of
polyglutamic acid, which maximizes the drug loading efficiency and reduces the polymer
heterogeneity. The traditional polyglutamic acid CPT conjugation method, however, can
only achieve 20 – 30% conjugation efficiency (calculated from the loading capacity) [37,
52]. Moreover, 100% CPT conjugation in the graft copolymer completely masked the
carboxylic acid residues of polyglutamic acid, making the graft copolymer, as well as the
nanocarrier, electrically neutral. The partial conjugation in traditional methods, however,
always maintained some free carboxylic acid groups and makes the polymer negatively
charged, which might adversely affects the cellular uptake and in vivo biodistribution [53–
55]. The resulting graft copolymer presented a well-controlled structure and relatively
narrow distributed molecular weight (Figure 1B and Table 1). The content of CPT in the
graft copolymer can be readily tuned by the side-chain length which was controlled by the
feed ratios during the second-step polymerization. As shown in Table 1, the graft copolymer
MB-10 (“MB” designates multiblock, 10 indicates the second-step polymerization feed ratio
of monomer III is 10/1) showed a CPT loading capacity of 15.2wt%. By increasing the feed
ratio to 20/1 (designated as MB-20), the CPT loading capacity was tuned as 23.9 wt%.
However, when further increasing feed ratio to 30/1 (designated as MB-30), only slightly
enhanced the drug loading capacity (25.1 wt%), which might be caused by the declined
efficiency of ROP as the side chains elongated [56].
3.2. Graft copolymer folding and nanocarrier characterization
To fold the graft copolymer and encapsulate Dox, graft copolymer and Dox were dissolved
into organic solvent NMP and then simply mixed with large quantities of water. Together
with Dox encapsulation, the folding was processed instantly and efficiently. All the three
graft copolymers showed strong encapsulation capability toward Dox. Within MB-20’s
folding, as much as 30.0 wt% of Dox (percentage of Dox weight compared to polymer) can
be encapsulated into the nanocarriers. The structure of the nanocarriers was characterized by
the TEM imaging. The nanocarriers folded by MB-20 (Dox: 10 wt%) appeared as
monodispersed particles with a diameter of around 50 nm, which was in good agreement
with the results determined by the DLS assay (Figure 3A). In addition, nanocarriers with
either CPT only or two drugs exhibited good stability at 37 °C up to 5 days (Figure 4). The
folding process of graft copolymers can be monitored by the dye micellization (Figure 3B)
[43]. Dye merocyanine 540 is known to show a shift of the maximum wavelength (λmax)
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during the formation of micelle [57–58]. As shown in Figure 3B, the absorbance intensity of
the micelled dye peak at 575 nm, associated with a micellar environment, steadily increased
as the concentration of the graft copolymer increased, clearly indicating the formation of a
micelle-like folded nanostructure. Furthermore, the core-shell corona structure of the
nanocarriers was characterized by 1H NMR spectra and fluorescence dequenching assay. As
shown in Figure 3C, the proton of CPT, polypeptide and PEG segments were clearly
detectable under “Sd” in deuterated dimethyl sulfoxide (DMSO-d6). In contrast, only signals
associated with PEG was detected under “Sn” in deuterated water (D2O), further indicating a
core-shell structure of the nanocarrier in water [42]. The folded structure was also confirmed
by fluorescence dequenching measurement, as shown in Figure 3D and E. When the graft
copolymer folded into nanocarriers, the hydrophobic side chains as well as the Dox
molecules were expected to stack together to form a hydrophobic core. The drug
aggregation in the core caused the “static quenching effect” [59–60], which dramatically
decreased the fluorescence intensities of both CPT and Dox, as displayed in Figure 3D and
E. However, when the corona structure was disrupted by adding the surfactant SDS, the
fluorescence of CPT and Dox was substantially recovered (from “Sn” to “Sd”).
3.3. In vitro drug release
The in vitro CPT release kinetics of MB-20 was quantified by HPLC. The data in Figure 5A
indicated that less than 10% of CPT was released from nanocarriers in the presence of the
mouse serum within 6 days, indicating its high stability in the serum. In sharp contrast,
Glu(CPT)-OH, the monomer III derivative, showed a burst release profile of CPT, although
they had the same drug-ester linker, which provided a substantial evidence that the presence
of PEG shell around MB-20 was able to effectively shield off esterase attack and prevent
premature drug release. In addition, the encapsulated Dox displayed a preferential release
under a weak-acid condition, as depicted in Figure 5B. This accelerated release under an
acidic condition was attributed to the re-protonation of the amino group of Dox and its
subsequently higher aqueous solubility at a lower pH value [35, 61]. Providing the route that
the nanocarriers were trapped in endosomes (pH 5–6) and lysosomes (pH 4–5) after cellular
uptake, the acid-facilitated release can be a benefit to the enhanced cytotoxicity.
3.4. In vitro cytotoxicity
As shown in Table 2, MB-20 and MB-20/Dox exhibited potent in vitro cytotoxicity against a
panel of 9 cancer cell lines. CPT showed potent cytotoxicity in most of the cancer cell lines,
with IC50 ranging from 0.02 to 3.30 μM. Interestingly, MB-20 exhibited comparable or only
slightly weaker potency than CPT, with the exception of cell line MDA-MB-231. Since the
ester linker cleavage is the prerequisite for MB-20 to elicit its activity, the results
demonstrated that CPT of nanocarriers is releasable in cancer cells. After co-delivery with
Dox, nanocarrier MB-20/Dox presented 1.5- to 60-fold more potent than MB-20, confirming
the enhanced anticancer efficacy of the co-delivery system.
3.5. Cellular uptake and intracellular nanocarrier tracking
The drug accumulation and subcellular localization of nanocarriers were determined by the
in vitro uptake study and CLSM observation. As shown in Figure 6A, the accumulated
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uptake of CPT and Dox in A549 cells was gradually increased over the uptake time.
Moreover, the molar ratio of the cellular accumulated CPT and Dox at most time points in
Figure 6A was around 2.1/1, which well agreed with the drugs’ molar ratios in nanocarriers,
indicating that the nanocarrier was internalized by the cancer cells without significant
premature leakage of Dox. To elucidate the uptake pathway of the nanocarrier, several
specific endocytic inhibitors were used. As shown in Figure 6B, sucrose and chlorpromazine
(clathrin-mediated endocytosis inhibitors) [62–63] reduced the uptake of nanocarrier by
about 70% and 50%, respectively. In contrast, insignificant inhibition on the cellular uptake
of nanocarrier was found in the cells pretreated with nystatin (an inhibitor of caveolin-
mediated endocytosis) [64] or sodium azide/2-deoxyglucose and wortmannin (inhibitors of
macropinocytosis) [65–66]. Additionally, the uptake of nanocarrier was strongly inhibited
by the lipid raft inhibitor, methyl-β-cyclodextrin [67]. The similar phenomenon was also
observed in the cellular uptake of other polymeric micelles [68]. These results indicated that
lipid raft and clathrin-mediated endocytosis might play a major role in the internalization of
the nanocarrier. Similar to the observation of in vitro uptake study in Figure 6A, the
fluorescence of CPT and Dox in cells gradually increased until reaching the plateau at 4 h.
The CLSM images at 1 h pointed out that the fluorescence of CPT (blue) and Dox (red) was
well merged with that of LysoTracker (green), revealing that nanocarriers were mainly
localized in the acidic organelles (endosomes and lysosomes) at the first hour of incubation.
After 4 h of incubation, parts of drugs migrated outside from endosomes/lysosomes as
evidenced by the presence of CPT and Dox fluorescence beyond acidic organelles (Figure
6C). Further incubation lead to more escape of drugs from lysosomes at 8 h. A considerable
amount of nanocarriers/drugs are still trapped in the acidic organelles, which might be
attributed by the lack of endosome/lysosome disrupting feature in the nanocarrier. However,
lysosome might play important roles in the drug release. The free drugs might be released
through degradation of polymers by lysosomal enzymes, followed by diffusion of the active
agents into the cytoplasm [69].
3.6. In vivo evaluation in lung tumor
The in vivo accumulation of nanocarrier in tumor was evaluated by the near-IR optical
imaging. The N-terminals of the side chains in the graft copolymer MB-20 were labeled with
Cy5.5, and the resulting graft copolymer was folded into nanocarriers which were then
intravenously administered into the mice bearing the A549 tumor model. The mice receiving
MB-20/Cy5.5 nanocarriers displayed strong fluorescence at the tumor sites after 4 h (Figure
7A). To assess biodistribution, tumors and other tissues were harvested for ex vivo imaging
at 72 h post injection (Figure 7B). The quantitative analysis in Figure 7C showed that the
tumor exhibited significantly higher accumulation of nanocarrier than heart, spleen and
kidney. Furthermore, the anticancer efficacy of nanocarriers was assessed toward A549
tumor-bearing nude mice via tail vain injection of different formulations. Compared with the
groups treated with PBS, CPT and Dox, the single-drug nanocarrier MB-20 and dual-drug
nanocarrier MB-20/Dox possessed significantly higher anti-tumor activities (Figure 7D),
regardless of their comparable IC50 values on cancer cells in vitro (Table 2). Noticeably, the
dual-drug nanocarrier exhibited a significantly higher tumor inhibition than single-drug
loaded MB-20. Moreover, the current platform can dramatically increase the administration
dose of CPT to more than 10 mg/kg, which is usually intolerable by mice if injected as a free
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drug [70]. These results revealed that graft copolymer folded nanocarrier produced
measurable inhibitory effect on tumor growth, and their therapeutic efficacy might be
attributed to the superior accumulation at tumor sites and insignificant toxicity in vivo
(Figure 7E).
4. Conclusion
In summary, we have designed and synthesized a new nanocarrier “folded” from a graft
copolymer. CPT was “purely” polymerized on the side chain of the graft polymer, while
Dox was non-covalently encapsulated in the hydrophobic core. This nanocarrier
demonstrated a series of attractive properties as an anticancer drug delivery vehicle,
including ease of preparation, uniform formulation, high loading capacity of drugs, good
stability, PEG-based stealth character and tumor accumulation ability [71].
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Schematic design of graft copolymer synthesis and stealth nanocarrier folding. (A) Graft
copolymer with pendant drug segment is synthesized from three monomers by a two-step
polymerization, and then folds into nanostructure with free doxorubicin encapsulated. (B)
The chemical structure of graft copolymer. The graft copolymer is comprised of a PEG-
containing multiblock copolymer main chain and the polyglutamic acid-based side chains
with “purely” conjugated camptothecin.
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The synthetic schemes of graft copolymer 5 and monomer III. Monomer I and Monomer II
were firstly condensed into a linear alternating multiblock copolymer by NHS mediated
amidation. After liberating the third amino group of monomer I, the side chains were
gradually elongated on the main chain via a TMS controlled ROP of monomer III. To
maximize the drug loading capacity, CPT was conjugated with glutamic acid and directly
polymerized into the side chain, presenting a new method for drug loading.
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Characterization of graft copolymer and its folded structure. (A) The hydrodynamic size of
MB-20/Dox measured by DLS. Inset: the TEM image of the folded nanocarriers
encapsulated with Dox (MB-20/Dox). Scale bar: 100 nm. (B) Absorbance spectra of
merocyanine 540 in aqueous solution of graft copolymer MB-20. The maximum wavelength
(λmax) shifted toward 575 nm as the polymer concentration increased (from bottom to top: 0
to 1 mg/mL). (C) 1H NMR spectra of graft copolymer (MB-20) in DMSO-d6 (“denatured”
state, Sd) and its folded nanocarrier in D2O (“native” state, Sn). Insert shows the NMR
signals of CPT in the side chains. (D)–(E) The fluorescence spectra of CPT (D) and Dox (E)
in nanocarriers after disrupting the structure of nanocarriers by SDS. Insets: plots of
recovery fluorescence intensities over time (CPT: monitored at Ex/Em=370/418 nm; Dox:
monitored at Ex/Em=480/596 nm).
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The hydrodynamic size of MB20 and MB-20/Dox measured by DLS over time. The data
were expressed as mean ± SD (n=3).
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(A) The CPT release from Glu(CPT) and MB-20 nanocarrier in 100% mouse serum at 37
°C. MB-20 nanocarrier has the same drug ester linkage with Glu(CPT). However, its ester
linkage is protected by PEG shell and prevented from the esterase attack, resulting in better
stability in the serum. (B) The accumulative release of Dox from MB-20/Dox nanocarrier
over time at different pH buffers at 37 °C.
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The cellular uptake behavior of nanocarriers (MB-20/Dox) toward cancer cells. (A) The
accumulated uptake of MB-20/Dox in A549 cells was steadily increased over the uptake
time. (B) The relative uptake efficiency of nanocarriertowardA549 cells in the presence of
various endocytosis inhibitors. SUC: sucrose; CPZ: chlorpromazine; NYS: nystatin; MβCD:
methyl-β-cyclodextrin; NaN3/DOG: sodium azide/2-deoxyglucose; WORT: wormannin. *p
< 0.01 with respect to control groups. (C) Cellular internalization of MB-20/Dox toward
A549 cells at different time observed by CLSM. The late endosomes and lysosomes were
stained by LysoTracker Green. Scale bar: 10 μm. The data were expressed as mean ± SD
(n=3).
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In vivo biodistribution and anti-tumor efficacy of nanocarriers in tumor-bearing mice. (A)
Near-IR optical imaging of A549 tumor-bearing nude mice at 4, 24, 48 and 72 h after
intravenous injection of MB-20/Cy5.5 at Cy5.5 dose of 26 nmol/kg. The red arrow in the
light phase indicated the tumor site. (B) Ex vivo imaging of tumors and other tissues of A549
tumor-bearing nude mice at 72 h post injection. (C) The quantitative analysis of
fluorescence signals from tumors and other tissues. Values are means ± SD (n=3). *p < 0.05
with respect to heart, spleen and kidney groups. (D) The A549 tumor growth curves after
treating with either PBS, CPT, Dox, MB-20 nanocarrier or MB-20/Dox nanocarrier. Values
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are means ± SEM (n=5). *p< 0.05 compared to PBS, CPT and Dox groups; +p < 0.05
compared to MB-20. (E) The body weight variation of mice after treated with different
formulations.
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